Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers(Neo-Chance Study)

NCT04196465 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT04196465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04196465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers(Neo-Chance Study)
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 9, 2019
Completion date
September 26, 2026
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

subjects with resectable and localized gastric cancer, subjects with resectable esophageal cancer or liver cancer, subjects with resectable liver cancer